Alvotech Resubmits Biologics License Applications for Biosimilars
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Application Resubmission: Alvotech announced the resubmission of Biologics License Applications for AVT05 and AVT06 to the FDA, with AVT05 being a biosimilar to Simponi® and AVT06 to Eylea®, demonstrating the company's ongoing commitment to the biosimilars market.
- Partnership Dynamics: The collaboration with Teva Pharmaceuticals allows Alvotech to focus on the development and manufacturing of AVT05 and AVT06 while Teva handles commercialization, which is expected to accelerate product launches and enhance market competitiveness.
- Quality System Enhancement: Following a routine FDA inspection in May 2026, Alvotech has strengthened its quality systems and manufacturing operations, indicating a sustained investment in improving production standards and compliance, which is likely to positively impact future regulatory approvals.
- Market Outlook: The resubmission of AVT05 and AVT06 is expected to undergo a six-month review period, and if approved, will provide significant opportunities for market share growth in the biosimilars sector, further solidifying Alvotech's position in the global biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 33.080
Low
29.00
Averages
35.71
High
40.00
Current: 33.080
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alvotech Resubmits Biologics License Applications for Biosimilars
- Application Resubmission: Alvotech announced the resubmission of Biologics License Applications for AVT05 and AVT06 to the FDA, with AVT05 being a biosimilar to Simponi® and AVT06 to Eylea®, demonstrating the company's ongoing commitment to the biosimilars market.
- Partnership Dynamics: The collaboration with Teva Pharmaceuticals allows Alvotech to focus on the development and manufacturing of AVT05 and AVT06 while Teva handles commercialization, which is expected to accelerate product launches and enhance market competitiveness.
- Quality System Enhancement: Following a routine FDA inspection in May 2026, Alvotech has strengthened its quality systems and manufacturing operations, indicating a sustained investment in improving production standards and compliance, which is likely to positively impact future regulatory approvals.
- Market Outlook: The resubmission of AVT05 and AVT06 is expected to undergo a six-month review period, and if approved, will provide significant opportunities for market share growth in the biosimilars sector, further solidifying Alvotech's position in the global biopharmaceutical industry.
See More
UroGen Pharma Settles Patent Dispute with Teva Pharmaceuticals
- Patent Dispute Resolution: UroGen Pharma has reached a settlement with Teva Pharmaceuticals to resolve a patent dispute over its cancer therapy Jelmyto, ensuring UroGen's market exclusivity in the U.S. until April 15, 2027.
- Market Access Arrangement: As part of the settlement, Teva will receive a non-exclusive license to market its generic version starting September 15, 2030, pending FDA approval, which will provide Teva with a new revenue stream.
- Litigation Dismissal: The parties will request the court to dismiss the litigation with prejudice, meaning similar claims cannot be refiled, thereby reducing future legal risks and uncertainties.
- Market Impact Assessment: This settlement not only protects UroGen's market share but may also influence Teva's branding strategy, marking a further expansion into the generic drug market and enhancing its competitiveness in cancer treatment.
See More
Teva CEO to Participate in Goldman Sachs Healthcare Conference
- Goldman Sachs Conference Participation: Teva's CEO Richard Francis will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026, starting at 8:00 A.M. Eastern Time, showcasing the company's strategic direction in the healthcare sector.
- Investor Relations Transparency: The conference will be webcast live on Teva's Investor Relations website, with archived versions available within 24 hours post-event, enhancing communication between the company and its investors by providing timely updates.
- Company Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, committed to addressing patient needs through its world-class generics business, demonstrating its innovation capabilities in neuroscience and immunology.
- Caution on Forward-Looking Statements: Teva cautions investors regarding its forward-looking statements, highlighting that future performance may be influenced by various risks and uncertainties, ensuring that investors maintain a cautious outlook on the company's future developments.
See More
Teva Pharmaceutical's Strong Comeback
- Significant Sales Growth: In 2025, Teva's overall sales reached $17.3 billion, with only a 5% increase; however, adjusted EBITDA and non-GAAP earnings per share grew by 12% and 19%, respectively, indicating improved profitability.
- Strong Branded Drug Sales: Sales for Teva's flagship branded drugs, Austedo, Uzedy, and Ajovy, increased by 41%, 62%, and 35%, respectively, demonstrating the success of the company's transformation into higher-margin pharmaceuticals.
- Debt Reduction Achieved: Over the past four years, Teva has reduced its net debt by more than $5.5 billion, from $18.4 billion on December 31, 2022, to $12.9 billion on March 31, 2026, enhancing the company's financial stability.
- Future Growth Potential: Analysts forecast a 30.8% growth in earnings per share for 2027, while the $700 million acquisition of Emalex Biosciences adds a potential blockbuster drug to Teva's portfolio, further driving earnings growth.
See More
Teva Pharmaceutical's Transformation Fuels Stock Rebound
- Significant Sales Growth: In 2025, Teva Pharmaceutical reported overall sales of $17.3 billion, with a modest 5% increase; however, adjusted EBITDA and non-GAAP earnings per share grew by 12% and 19%, respectively, indicating a notable improvement in profitability.
- Strong Branded Drug Sales: Teva's flagship branded drugs, Austedo, Uzedy, and Ajovy, achieved sales growth of 41%, 62%, and 35% in the latest earnings report, demonstrating the company's successful pivot towards higher-margin pharmaceuticals.
- Ongoing Debt Reduction: Over the past four years, Teva has reduced its net debt by more than $5.5 billion, from $18.4 billion in December 2022 to $12.9 billion in March 2026, enhancing its financial health and providing greater flexibility for future growth.
- Acquisition of Potential Blockbuster: Teva's acquisition of Emalex Biosciences for $700 million adds the potential blockbuster drug ecopipam to its portfolio, further diversifying its product line and potentially driving future revenue growth, reflecting the company's proactive strategy in expanding its drug offerings.
See More
Teva and Medincell Submit Drug Application for Schizophrenia Treatment
- Drug Application Progress: Teva Pharmaceuticals International GmbH and Medincell announced that the European Medicines Agency has accepted their Marketing Authorization Application for the long-acting injectable olanzapine (TEV-'749), marking a significant advancement in the treatment of schizophrenia in adults.
- Technological Innovation: TEV-'749 utilizes Medincell's proprietary SteadyTeq copolymer technology, which enables controlled, steady, and prolonged release of olanzapine, expected to significantly enhance patient adherence and treatment outcomes.
- Clinical Support: The submission is backed by an extensive clinical development program, including the Phase 3 SOLARIS study, indicating that the drug has demonstrated good safety and efficacy in clinical trials.
- Market Dynamics: Although TEV-'749 has not yet been approved by any regulatory authority worldwide, Medincell's shares were trading at 26.62 euros, down 1.19% at the last close, reflecting market caution regarding the drug's future prospects.
See More
Alvotech Resubmits Biologics License Applications for Biosimilars
- Application Resubmission: Alvotech announced the resubmission of Biologics License Applications for AVT05 and AVT06 to the FDA, with AVT05 being a biosimilar to Simponi® and AVT06 to Eylea®, demonstrating the company's ongoing commitment to the biosimilars market.
- Partnership Dynamics: The collaboration with Teva Pharmaceuticals allows Alvotech to focus on the development and manufacturing of AVT05 and AVT06 while Teva handles commercialization, which is expected to accelerate product launches and enhance market competitiveness.
- Quality System Enhancement: Following a routine FDA inspection in May 2026, Alvotech has strengthened its quality systems and manufacturing operations, indicating a sustained investment in improving production standards and compliance, which is likely to positively impact future regulatory approvals.
- Market Outlook: The resubmission of AVT05 and AVT06 is expected to undergo a six-month review period, and if approved, will provide significant opportunities for market share growth in the biosimilars sector, further solidifying Alvotech's position in the global biopharmaceutical industry.
See More
UroGen Pharma Settles Patent Dispute with Teva Pharmaceuticals
- Patent Dispute Resolution: UroGen Pharma has reached a settlement with Teva Pharmaceuticals to resolve a patent dispute over its cancer therapy Jelmyto, ensuring UroGen's market exclusivity in the U.S. until April 15, 2027.
- Market Access Arrangement: As part of the settlement, Teva will receive a non-exclusive license to market its generic version starting September 15, 2030, pending FDA approval, which will provide Teva with a new revenue stream.
- Litigation Dismissal: The parties will request the court to dismiss the litigation with prejudice, meaning similar claims cannot be refiled, thereby reducing future legal risks and uncertainties.
- Market Impact Assessment: This settlement not only protects UroGen's market share but may also influence Teva's branding strategy, marking a further expansion into the generic drug market and enhancing its competitiveness in cancer treatment.
See More
Teva CEO to Participate in Goldman Sachs Healthcare Conference
- Goldman Sachs Conference Participation: Teva's CEO Richard Francis will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 8, 2026, starting at 8:00 A.M. Eastern Time, showcasing the company's strategic direction in the healthcare sector.
- Investor Relations Transparency: The conference will be webcast live on Teva's Investor Relations website, with archived versions available within 24 hours post-event, enhancing communication between the company and its investors by providing timely updates.
- Company Transformation Strategy: Teva is transforming into a leading innovative biopharmaceutical company, committed to addressing patient needs through its world-class generics business, demonstrating its innovation capabilities in neuroscience and immunology.
- Caution on Forward-Looking Statements: Teva cautions investors regarding its forward-looking statements, highlighting that future performance may be influenced by various risks and uncertainties, ensuring that investors maintain a cautious outlook on the company's future developments.
See More
Teva Pharmaceutical's Strong Comeback
- Significant Sales Growth: In 2025, Teva's overall sales reached $17.3 billion, with only a 5% increase; however, adjusted EBITDA and non-GAAP earnings per share grew by 12% and 19%, respectively, indicating improved profitability.
- Strong Branded Drug Sales: Sales for Teva's flagship branded drugs, Austedo, Uzedy, and Ajovy, increased by 41%, 62%, and 35%, respectively, demonstrating the success of the company's transformation into higher-margin pharmaceuticals.
- Debt Reduction Achieved: Over the past four years, Teva has reduced its net debt by more than $5.5 billion, from $18.4 billion on December 31, 2022, to $12.9 billion on March 31, 2026, enhancing the company's financial stability.
- Future Growth Potential: Analysts forecast a 30.8% growth in earnings per share for 2027, while the $700 million acquisition of Emalex Biosciences adds a potential blockbuster drug to Teva's portfolio, further driving earnings growth.
See More
Teva Pharmaceutical's Transformation Fuels Stock Rebound
- Significant Sales Growth: In 2025, Teva Pharmaceutical reported overall sales of $17.3 billion, with a modest 5% increase; however, adjusted EBITDA and non-GAAP earnings per share grew by 12% and 19%, respectively, indicating a notable improvement in profitability.
- Strong Branded Drug Sales: Teva's flagship branded drugs, Austedo, Uzedy, and Ajovy, achieved sales growth of 41%, 62%, and 35% in the latest earnings report, demonstrating the company's successful pivot towards higher-margin pharmaceuticals.
- Ongoing Debt Reduction: Over the past four years, Teva has reduced its net debt by more than $5.5 billion, from $18.4 billion in December 2022 to $12.9 billion in March 2026, enhancing its financial health and providing greater flexibility for future growth.
- Acquisition of Potential Blockbuster: Teva's acquisition of Emalex Biosciences for $700 million adds the potential blockbuster drug ecopipam to its portfolio, further diversifying its product line and potentially driving future revenue growth, reflecting the company's proactive strategy in expanding its drug offerings.
See More
Teva and Medincell Submit Drug Application for Schizophrenia Treatment
- Drug Application Progress: Teva Pharmaceuticals International GmbH and Medincell announced that the European Medicines Agency has accepted their Marketing Authorization Application for the long-acting injectable olanzapine (TEV-'749), marking a significant advancement in the treatment of schizophrenia in adults.
- Technological Innovation: TEV-'749 utilizes Medincell's proprietary SteadyTeq copolymer technology, which enables controlled, steady, and prolonged release of olanzapine, expected to significantly enhance patient adherence and treatment outcomes.
- Clinical Support: The submission is backed by an extensive clinical development program, including the Phase 3 SOLARIS study, indicating that the drug has demonstrated good safety and efficacy in clinical trials.
- Market Dynamics: Although TEV-'749 has not yet been approved by any regulatory authority worldwide, Medincell's shares were trading at 26.62 euros, down 1.19% at the last close, reflecting market caution regarding the drug's future prospects.
See More
